Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

Table 3 Correlations between biomarkers expressed as P values (Chi square test)

	MET overexpression	p-MET overexpression	HGF overexpression	MET amplification
MET overexpression		0.013	0.517	0.004
p-MET overexpression	0.013		0.001	0.047
HGF overexpression	0.517	0.001		0.786
MET amplification	0.004	0.047	0.786

ISSN: 1479-5876